Can angiotensin receptor antagonists prevent restenosis after stent placement?

American Journal of Cardiovascular Drugs

Volumn 2, Issue 3, 2002, Pages 143-148

  Peters, Stefan ^a  

^a UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOPEPTIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CILAZAPRIL; CIPROSTENE; COLCHICINE; CYTOKINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; GROWTH FACTOR; KETANSERIN; LOW MOLECULAR WEIGHT HEPARIN; MEVINOLIN; NIFEDIPINE; PACLITAXEL; PLACEBO; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; SEROTONIN 2 ANTAGONIST; SULOTROBAN; TACROLIMUS; THROMBOXANE RECEPTOR BLOCKING AGENT; UNINDEXED DRUG; VALSARTAN; VAPIPROST;

ARTERY DIAMETER; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHERECTOMY; BRACHYTHERAPY; CELL ACTIVATION; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG EFFICACY; DRUG TOLERABILITY; ECONOMIC ASPECT; ELUTION; HEALTH CARE COST; HUMAN; LEFT ANTERIOR DESCENDING CORONARY ARTERY; LONG TERM CARE; NEUTROPHIL; PATHOPHYSIOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; PROTEIN INTERACTION; RESTENOSIS; RISK ASSESSMENT; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0036319271     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200202030-00001     Document Type: Article

References (77)

1. A randomized comparison of coronary stent-placement and balloon angioplasty in the treatment of coronary artery disease
2. A comparison of balloon-expandable stent implantation with balloon angioplasty in patients with coronary artery disease
3. Stents: A mechanical solution for a biological problem? Sigwart U
4. Procedural and follow-up results with a new balloon expandable stent in unselected lesions
5. A comparison of the costs and quality of life after coronary angioplasty or coronary surgery for multivessel coronary artery disease: Results from the Emory angioplasty versus surgery trial (EAST)
6. A paradigm for restenosis based on cell biology: Clues for the development of new preventive therapies
7. Restenosis after percutaneous transluminal coronary angioplasty: Pathologic observations in 20 patients
8. Predictive factors of restenosis after coronary stent placement
9. Restenosis after coronary stenting in current clinical practice
10. Predictors of restenosis after coronary stent implantation
11. Angiographic and clinical outcome of intracoronary stenting: Immediate and long-term results from a large single center experience
12. Potential mechanisms promoting restenosis in diabetic patients
13. Effect of diabetes mellitus on outcome after percutaneous transluminal coronary angioplasty
14. Combined antiplatelet therapy with ticlopidine and aspirin: A simplified approach to intracoronary stent management
15. The varying behaviour of stent thrombosis in native arteries versus aorto-coronary saphenous vein bypass grafts
16. Impact of high inflation pressures on six-month angiographic follow-up after coronary stent placement
17. Influence of residual stenosis after PTCA and stent implantation on stent thrombosis rate and restenosis rate
18. Influence of lesion length on late angiographic outcome and restenotic process after successful stent implantation
19. Cutting balloon angioplasty for the treatment of in-stent-restenosis: A matched comparison with rotational atherectomy, additional stent implantation and balloon angioplasty
20. Three-year clinical and angiographic follow-up after intracoronary radiation: Results of a randomized clinical trial
21. Combination of lovastatin, enalapril, and colchicine does not prevent restenosis after percutaneous transluminal coronary angioplasty
22. The effect of porous infusion balloon-delivered angiopeptin on myointimal hyperplasia after balloon injury in the rabbit
23. Longterm effects of angiopeptin treatment in coronary angioplasty: Reduction of clinical events but not angiographic restenosis
24. Effects of nifedipine on recurrent stenosis after percutaneous transluminal coronary angioplasty
25. Effects of diltiazem on complications and restenosis after coronary angioplasty
26. Determinants of restenosis and lack of effect of dietary Supplementation with eicosapentaenoic acid in the incidence of coronary artery restenosis after angioplasty
27. Randomised trial of fish oil for prevention of restenosis after coronary angioplasty
28. Double-blind, randomised, controlled trial of fish oil Supplements in prevention of recurrence of stenosis after coronary angioplasty
29. Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty
30. Low molecular weight heparin in prevention of restenosis after angioplasty: Results of enoxaparin restenosis (ERA) trial
31. Lack of effect of lovastatin on restenosis after coronary angioplasty: Lovastatin restenosis trial study group
32. The effect of lovastatin on early restenosis
33. Effect of short-term prostacyclin administration on restenosis after percutaneous transluminal coronary angioplasty
34. Ciprostene Investigators. Ciprostene for restenosis revisited: Quantitative analysis of angiograms for the
35. Effect of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty: A multicenter randomised double-blind placebo-controlled trial
36. Multi-Hospital Eastern Atlantic Restenosis Trial II: A placebo-controlled trial of thromboxane blockade in the prevention of restenosis following coronary angioplasty
37. Prevention of restenosis after percutaneous transluminal coronary angioplasty with thromboxane A2-receptor blockade. A randomized, double-blind, placebo-controlled trial. Coronary Artery Restenosis Thromboxane-Antagonism Study (CARPORT)
38. Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesions
39. Intracoronary radiation bevor stent implantation inhibits neointima formation in stented porcine coronary arteries
40. Intravascular low power red laser light as an adjunct to coronary stent implantation evaluated in a porcine coronary model
41. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II)
42. Comparison of coronary bypass surgery and stenting for the treatment of multivessel disease
43. Primary stenting versus balloon angioplasty in occluded coronary arteries: The Total Occlusion Study of Canada (TOSCA)
44. Coronary angioplasty with or without stent implantation for acute myocardial infarction
45. The RAVEL study: A randomized study with sirolimus-eluting Bx velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions
46. 210-day follow-up of the RAVEL study: A randomized study with sirolimus-eluting Bx velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions
47. The clinical effectiveness of paclitaxel-coated coronary stents for the reduction of restenosis in the ASPECT tria, [Oral presentation]
48. European evaluation of paclitaxel-eluting stent
49. Influence of the angiotensin system on endothelial and smooth muscle cell migration
50. Pharmacological strategies to prevent restenosis: Lessons learned from blockade of the renin-angiotensin system
51. Induction of endothelin secretion by angiotensin II: Effects on growth and synthetic activity of vascular smooth muscle cells
52. An insertion/deletion polymorphism in the angiotensin I: Converting enzyme gene accounting for half the variance of serum enzyme levels
53. Plasma activity and insertion/deletion polymorphism of angiotensin I: Converting enzyme: A major risk factor and a marker of risk for coronary stent restenosis
54. Induction of cytokine expression in leukocytes in acute myocardial infarction
55. Kinetics of tumor necrosis factor alpha in plasma and the cardioprotective effect of a monoclonal antibody to tumor necrosis factor alpha in acute myocardial infarction
56. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques
57. Platelet and leukocyte activation after myocardial infarction. Influence of enalapril
58. AT1 receptor blockade in experimental myocardial ischemia/reperfusion
59. Inflammatory response, neutrophil activation, and free radical production after acute myocardial infarction: Effect of thrombolytic treatment
60. OPTIMAAL Trial Steering Committee and Investigators. Comparison of baseline data, initial course, and management losartan versus captopril following acute myocardial infarction (the OPTIMAAL Trial)
61. Valsartan in acute myocardial infarction trial (VALIANT): Rationale and design
62. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury
63. Vascular injury augments adrenergic neuro-transmission
64. Inhibition of converting enzyme and neointima formation after vascular injury in rabbits and guinea pigs
65. Effects of subtype-selective and balanced angiotensin II receptor antagonists in a porcine coronary artery model of vascular restenosis
66. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: A multicenter, randomized, double-blind placebo-controlled trial
67. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: Final results of the MARCATOR study, a multi-center, double-blind, placebo-controlled trial of cilazapril
68. Beneficial effect of quinapril in patients with angiotensin-converting enzyme D allele after coronary stenting
69. Effect of ACE inhibitors on angiographic restenosis after coronary stenting (PARIS): A randomised, double-blind, placebo-controlled trial
70. Bradykinin receptor antagonists attenuate neointimal proliferation postangioplasty
71. Valsartan for prevention of restenosis after stenting of type B2/C lesions: The ValPREST Trial
72. Angiotensin II AT2 subtype receptors: An emerging target for cardiovascular therapy
73. Effects of valsartan and 17 beta-estradiol on the oxidation of low-density lipoprotein in vitro
74. CV-11974, the active metabolite of TCV-116 (Candesartan), inhibits the synergistic or additive effect of different growth factors on angiotensin II-induced proliferation of vascular smooth muscle cells
75. Losartan, a selective inhibitor of subtype AT1 receptors for angiotensin II, inhibits the binding of N-formyl-methionyl-leucyl-phenylalanine to neutrophil receptors
76. Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure
77. Changes of plasma endothelin and growth factor levels, and left ventricular mass, after chronic AT1 -receptor blockade in human hypertension